Search results for "Vaccinations"
New research on Pfizer pill, mental disorders after COVID-19, vaccine reactions
A manufacturer-funded trial quantified the effectiveness of nirmatrelvir/ritonavir in outpatients. A retrospective study found veterans had more mental health diagnoses and received more antidepressants, benzodiazepines, and opioids after COVID-19, while two other studies looked at reactions to second and third doses of the vaccines.
https://immattersacp.org/weekly/archives/2022/02/22/1.htm
22 Feb 2022
Studies assess responses, reactions to vaccines; long-term effects of COVID-19 infection
Recent COVID-19 vaccine studies showed good response in pregnant women, as well as possible localized rashes from the Moderna vaccine. Analyses of ICU patients and those treated at a post-COVID-19 clinic highlighted the long-term effects of the virus, and a study found that dialysis patients maintained antibodies six months after COVID-19 infection.
https://immattersacp.org/weekly/archives/2021/05/18/1.htm
18 May 2021
Answers and even more questions on COVID-19 vaccines
In a fourth forum from ACP and Annals of Internal Medicine, infectious disease experts Carlos del Rio, MD, FACP, Paul Sax, MD, and Deborah Cotton, MD, MPH, FACP, discussed COVID-19 vaccines and their implementation, as well as other aspects of the pandemic response.
https://immattersacp.org/weekly/archives/2021/03/30/2.htm
30 Mar 2021
Pandemic enters new phase with end of PHE
COVID-19 isn't gone, but the end of the U.S. public health emergency does mark some significant changes.
https://immattersacp.org/archives/2023/06/pandemic-enters-new-phase-with-end-of-phe.htm
1 Jun 2023
Latest on COVID-19 and bamlanivimab, vaccines, long-term effects
Bamlanivimab reduced viral load in mild to moderate cases when combined with etesevimab, new vaccine recommendations, research, and educational resources were released, and two studies provided longer-term data on patients who had COVID-19.
https://immattersacp.org/weekly/archives/2021/01/26/1.htm
26 Jan 2021
New vaccine authorization and data, NIH on antibody treatment and ‘long COVID’
The Johnson & Johnson COVID-19 vaccine got an emergency use authorization, and an Israeli study provided more data on the Pfizer vaccine. The NIH recommended an antibody combo for outpatients and named long-term symptoms as post-acute sequelae of SARS-CoV-2 (PASC).
https://immattersacp.org/weekly/archives/2021/03/02/1.htm
2 Mar 2021
Clot concerns with adenovirus COVID-19 vaccines, antibody treatment recommendations and data
Based on reports of cerebral venous sinus thrombosis with the Johnson & Johnson (Janssen) COVID-19 vaccine, federal officials recommended a pause in its use, which will be reconsidered on April 23. The NIH updated its recommendations on monoclonal antibody treatments for outpatients.
https://immattersacp.org/weekly/archives/2021/04/20/1.htm
20 Apr 2021
Decrease in certain HPV types among unvaccinated women suggests herd protection
Prevalence of the four types of human papillomavirus (HPV) included in the original vaccine decreased most among women who were fully vaccinated but also decreased significantly among women who were unvaccinated between 2006 and 2017.
https://immattersacp.org/weekly/archives/2019/01/29/4.htm
29 Jan 2019
CDC issues interim guidance on measles infection control and prevention in health care
New government guidance covers what is acceptable evidence of immunity to measles and how to respond if health care personnel are exposed to the disease.
https://immattersacp.org/weekly/archives/2019/07/30/4.htm
30 Jul 2019
Risk of re-infection, benefits of anticoagulation, cause of sex differences among COVID-19 research
Researchers published evidence of re-infection with SARS-CoV-2, anticoagulation was associated with halved inpatient mortality, recommendations were made on pulmonary embolism in COVID-19, and a study attributed differences in men's and women's outcomes to T cells.
https://immattersacp.org/weekly/archives/2020/09/01/2.htm
1 Sep 2020